Recurrent genital herpes affects an estimated 81 to 98 cases per 100,000 person-years in the United States alone, yet the nucleoside analogues that have anchored standard care since acyclovir’s FDA approval in 1985 remain the backbone of treatment four decades later. That biochemical stasis is precisely the opening Innovative Molecules GmbH is targeting. The Munich-based company announced this week that the first patient has been dosed in its Phase 2a trial of adibelivir (IM-250) for recurrent genital herpes, moving the program from early safety work into proof-of-concept territory.
Adibelivir is a helicase-primase inhibitor, a mechanistic class that disrupts HSV replication by blocking the viral helicase-primase complex rather than mimicking nucleosides. That distinction matters clinically: patients who harbor acyclovir-resistant HSV strains carry mutations in viral thymidine kinase, which nucleoside analogues require for activation, and those mutations leave helicase-primase function completely intact. The Phase 2a study is designed to capture safety, antiviral activity, pharmacokinetics, and clinical efficacy simultaneously, a design that reflects the company’s need to demonstrate both target engagement and meaningful patient benefit in a single efficient cohort before committing to a larger registrational program.
The trial launch also arrives with a parallel pipeline signal worth noting. Innovative Molecules is advancing a novel antiviral program against Epstein-Barr virus, currently in IND-enabling activities, which extends the company’s herpesvirus franchise beyond HSV. That breadth is strategically relevant because it gives the platform a second clinical proof point without requiring a new mechanism: the helicase-primase complex is conserved across herpesviruses, meaning preclinical learnings from HSV can meaningfully inform EBV program design. The company raised a €20 million Series A in 2021 led by LSP, with EQT Life Sciences also represented on the advisory board, so the investor base already has appetite for a multi-asset herpesvirus story.
The single result to watch from the Phase 2a readout is antiviral activity measured as reduction in HSV shedding. Shedding frequency is the endpoint with the strongest track record for predicting downstream efficacy in suppression trials, and a clear signal there would give Innovative Molecules the mechanistic and clinical leverage it needs to move toward a pivotal design with confidence.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
